Company Description
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang.
It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
| Country | China |
| Founded | 2005 |
| IPO Date | Jan 4, 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Feng Zhou |
Contact Details
Address: 178 Taidong Road North Taizhou, 225300 China | |
| Phone | 86 523 8629 8290 |
| Website | sxtchina.com |
Stock Details
| Ticker Symbol | SXTC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001723980 |
| CUSIP Number | G2161P108 |
| ISIN Number | VGG2161P1403 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Feng Zhou | Chairman of the Board and Co-Chief Executive Officer |
| Xiaodong Pan | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Aug 7, 2025 | SCHEDULE 13G | Filing |
| Jul 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 15, 2025 | 6-K | Report of foreign issuer |
| Jun 16, 2025 | 6-K | Report of foreign issuer |
| May 19, 2025 | 424B5 | Filing |
| May 13, 2025 | 6-K | Report of foreign issuer |